Despite complex group of patients (59% ACS and 40% diabetics) and lesion subsets (40% restenotic lesions and 59% small vessels), this suggests SCBs can be used in both restenotic and de novo small vessel lesions with acceptable clinical outcomes. However, in order to further inform clinical practice, more longer-term data on SCBs compared with Paclitaxel coated balloons is needed.

Conflict of Interest None to declare